Radiotherapy review on National Surgical Adjuvant Breast and Bowel Project(NSABP) phase III breast cancer clinical trials - Is there a need for submission of portal/simulation films?
M. Deutsch et al., Radiotherapy review on National Surgical Adjuvant Breast and Bowel Project(NSABP) phase III breast cancer clinical trials - Is there a need for submission of portal/simulation films?, AM J CL ONC, 22(6), 1999, pp. 606-608
Citations number
1
Categorie Soggetti
Oncology
Journal title
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
In all National Surgical Adjuvant Breast and Bowel Project (NSABP) breast c
ancer trials in which patients are treated with lumpectomy and postoperativ
e breast irradiation, the quality assurance requirements dictate submission
of a completed radiotherapy data form with the stated administered doses,
the volumes treated, treatment prescription and daily treatment record shee
ts, dosimetry and calculation sheets, isodose distributions on the breast c
ontour, photos of the patient in the treatment position, and portal or simu
lation films. A review of radiotherapy data on 1,982 patients who had lumpe
ctomies accrued to seven recent NSABP breast cancer studies revealed only 2
patients who were judged to have inadequate fields. In both cases, a very
small portion of the breast tissue was not included in the irradiated volum
e as demonstrated by the submitted films. On this basis, it was argued that
submission of portal or simulation films for patients receiving postlumpec
tomy breast irradiation is not necessary. However, there was concern as to
the incidence of patients with a possible excess amount of lung tissue incl
uded in the irradiated volume. To address this concern, the amount of irrad
iated lung was determined for the first 208 patients who had lumpectomies,
with submitted data entered into the recent NSABP pathologic node-positive
protocol B-28. Current NSABP radiation therapy guidelines suggest limiting
the thickness of the irradiated lung in the portal beams to less than or eq
ual to 3 cm. Only two patients (<1%) were found to have >3 cm of irradiated
lung tissue in the treatment volume. Portal film submission is a considera
ble inconvenience to the individual institutions and is costly in terms of
shipping, handling, and storage. These results indicate that submission of
portal films is not a necessary part of quality assurance in NSABP breast c
ancer protocols. The NSABP has therefore eliminated the requirement for rou
tine submission of portal films in protocols for which radiotherapy is not
part of the rest question.